|
Jenex Corporation and UTEK Corporation Announce Strategic Alliance for Healthcare and Consumer Products Technology Transfer
BURLINGTON, ONTARIO & PLANT CITY, FL – (Business Wire) April 29, 2004 – Jenex Corporation (TSX-V: JEN), a company focused on developing unique consumer and healthcare products, and UTEK Corporation (AMEX: UTK), an innovative technology transfer company, announced jointly today the signing of a Strategic Alliance Agreement.
Michael Jenkins, Chief Executive Officer of Jenex Corporation, stated, “We are very pleased to retain UTEK to help identify proprietary technology acquisition opportunities to potentially expand our product line. In addition, Jenex will work closely with Pax Technology Transfer Ltd., a UTEK subsidiary located in the United Kingdom to identify potential partners or licensees for their Therapik® product for insect stings and bites.”
“UTEK looks forward to working with Jenex Corporation to identify technology acquisition and out-licensing opportunities that fit their strategic vision,” commented Clifford M. Gross, Ph.D., Chairman and Chief Executive Officer of UTEK.
Through its strategic alliance agreements, UTEK assists technology companies in enhancing their new product pipeline with the acquisition of proprietary intellectual capital from universities and laboratory research centers. Strategic alliances agreements are cancelable by either party with 30 days written notice.
About Jenex Corporation
Jenex Corporation, (“Jenex” or the “Company”) is a publicly traded Ontario-based medical device research and development company. Formed in 1999, Jenex is focused on the research and development of its patented thermal therapy technology. The first product developed from this technology was TherapikÒ. TherapikÒ has been approved as a Class II medical device in Canada and the United States with an approved stated purpose of stopping the pain, itch and inflammation caused by insect stings and bites. Through additional clinical trials and research, Jenex has developed another product from its technology that has been proven safe and effective in the prevention of Herpes Labialis (Cold Sores). For more information about Jenex Corporation, please visit their website at www.jenexcorp.com.
About UTEK Corporation
UTEKÒ is an innovative technology transfer company dedicated to building bridges between university-developed technologies and commercial organizations. UTEK, along with its TechEx and UVentures technology exchanges and its PAX European subsidiary, identifies and transfers new technologies from universities and research centers to the marketplace. UTEK provides research-outsourcing services to commercial enterprises and technology-transfer services to research institutions. For more information about UTEK, please visit our website at www.utekcorp.com.
Forward Looking Statements
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
Contacts:
Michael Jenkins, CEO John Baldissera
Jenex Corporation BPC Financial Marketing
905-632-3830 800-368-1217
|
